Table 3.
Group | Blood Glucose (mg/dL) | Plasma Insulin (μU/mL) | ||||
---|---|---|---|---|---|---|
1st Day | 22nd Day | 45th Day | 1st Day | 22nd Day | 45th Day | |
Group 1 | 91.3 ± 3.10 | 92.0 ± 3.60 | 92.4 ± 3.90 | 17.8 ± 0.73 | 17.1 ± 0.80 | 18.5 ± 0.61 |
Group 2 | 271 ± 3.20 a | 310 ± 4.90 a | 353 ± 4.10 ab | 9.21 ± 0.92 a | 6.43 ± 0.81 a | 5.31 ± 0.76 a |
Group 3 | 280 ± 3.80 a | 190 ± 4.10 ab | 98.6 ± 3.80 b | 8.90 ± 0.70 a | 12.5 ± 0.67 ab | 16.6 ± 0.79 b |
Group 4 | 277 ± 3.0 a | 247 ± 4.50 ac | 222 ± 4.30 abc | 9.89 ± 1.03 a | 9.32 ± 0.91 ac | 9.65 ± 1.03 ab |
Group 5 | 282 ± 3.40 a | 233 ± 4.30 abc | 190 ± 5.20 abc | 8.97 ± 1.07 a | 9.79 ± 1.04 abc | 10.9 ± 1.13 abc |
Group 6 | 278 ± 3.20 a | 212 ± 5.10 abc | 142 ± 4.70 abc | 9.03 ± 1.11 a | 10.4 ± 1.19 ab | 12.2 ± 1.08 ab |
Group 7 | 283 ± 3.80 a | 188 ± 4.70 ab | 107 ± 3.80 b | 8.80 ± 1.28 a | 12.0 ± 1.14 ab | 14.7 ± 1.16 ab |
Data are denoted as mean ± SEM (n = 6). a Significant (p < 0.05) difference compared to the normal group (Group 1). b Significant (p < 0.05) difference compared to the diabetic group (Group 2). c Significant (p < 0.05) difference compared to the glibenclamide-treated group (Group 3).